However, in the case of cancer therapy, as well as during infection, sustained lymphopenia triggered by S1PR1 antagonism may rather be disadvantageous, since T cells are needed at the tumor site for a proper anti-tumor response (224). This evidence concerns the gene S1PR1 and neoplasm.